A newly published correspondence in The Lancet is urging the medical community to draw a clearer line between two concepts that are often used interchangeably in discussions about rising cancer rates among younger people: adolescent and young adult (AYA) oncology and early-onset cancer. The authors argue that while the two categories overlap, they are not synonymous, and conflating them could lead to imprecise research, misdirected resources, and gaps in patient care.
The letter responds to a recent Lancet editorial that highlighted the growing cancer burden among younger populations. While welcoming the editorial's attention to the issue, the correspondents contend that the analysis would have been stronger had it distinguished between AYA oncology — a field focused on patients roughly between the ages of 15 and 39 — and early-onset cancer, which typically refers to cancers diagnosed in adults before the age of 50. The two groups share some characteristics, but they differ in biology, epidemiology, treatment protocols, and psychosocial needs.
AYA oncology has developed as a distinct discipline over the past two decades, recognizing that adolescents and young adults face unique challenges that differ from both pediatric and older adult cancer patients. These include issues related to fertility preservation, educational and career disruption, identity development, and long-term survivorship. Early-onset cancer, by contrast, is a broader epidemiological category that encompasses all cancers occurring at younger ages, regardless of the specific life stage of the patient. A 45-year-old with colon cancer and a 19-year-old with leukemia may both fall under the early-onset umbrella, but their clinical and personal circumstances are vastly different.
The correspondence suggests that failing to differentiate between these concepts can have real consequences. Research that lumps AYA patients together with all early-onset cases may obscure important age-specific trends, mask disparities in outcomes, and hinder the development of targeted interventions. Similarly, health policy that treats the two as identical may overlook the need for specialized AYA services, including age-appropriate psychosocial support, fertility counseling, and transition programs between pediatric and adult care.
The authors also point to the importance of precise terminology in communicating with the public and policymakers. As concern grows about rising cancer incidence among younger people, clear definitions become essential for setting research priorities and allocating funding. Conflating AYA oncology with early-onset cancer risks diluting the focus on each area and slowing progress in both.
The Lancet editorial had drawn attention to the increasing number of cancer diagnoses in people under 50, a trend that has been observed in multiple countries and cancer types. While the editorial called for greater awareness and action, the correspondence adds a note of methodological caution. It emphasizes that the causes, risk factors, and optimal management strategies may differ substantially across the age spectrum, and that a one-size-fits-all approach is unlikely to serve patients well.
The letter does not dispute the urgency of addressing rising cancer rates in younger populations. Instead, it calls for more nuanced language and more precise categorization in both research and clinical practice. By distinguishing AYA oncology from early-onset cancer, the authors argue, the medical community can better tailor its efforts to the specific needs of each group and avoid the pitfalls of oversimplification.
The correspondence reflects a broader conversation within oncology about how to define and study cancer in younger patients. As survival rates for many childhood cancers have improved, attention has shifted to the unique challenges faced by adolescents and young adults, who often fall into a gap between pediatric and adult care systems. At the same time, the rise in early-onset cancers of the breast, colon, and other organs has prompted new questions about environmental, lifestyle, and genetic factors.
For now, the authors' message is one of precision: overlapping concepts should not be treated as identical, and the distinctions matter for patients, researchers, and policymakers alike. The Lancet correspondence serves as a reminder that even subtle differences in terminology can shape the direction of medical research and the quality of care delivered to young people facing cancer.
9
